Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
89bio, Inc. - Common Stock
(NQ:
ETNB
)
7.550
+0.150 (+2.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 89bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
89bio Provides Business Update and Outlook for 2023
January 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
20 Favorite Biotech & Medical Stocks For 2023
December 28, 2022
The way these stocks are setting up, many of them look great and will be at the forefront this coming year.
Via
Talk Markets
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
7 Analysts Have This to Say About 89bio
September 14, 2022
89bio (NASDAQ:ETNB) has observed the following analyst ratings within the last quarter:
Via
Benzinga
US Stocks Slightly Lower; Nasdaq Down 100 Points
December 19, 2022
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 100 points on Monday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 19, 2022
Via
Benzinga
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology
December 12, 2022
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
From
89bio, Inc.
Via
GlobeNewswire
89bio's Pegozafermin Data Shows Improved Liver Fat, Glycemic Control
August 26, 2022
Via
Benzinga
Analysts Are Bullish On 89bio's NASH Data Slated For Early Next Year
August 18, 2022
Via
Benzinga
Analyst Ratings for 89bio
August 17, 2022
Within the last quarter, 89bio (NASDAQ:ETNB) has observed the following analyst ratings:
Via
Benzinga
6 Analysts Have This to Say About 89bio
August 17, 2022
Analysts have provided the following ratings for 89bio (NASDAQ:ETNB) within the last quarter:
Via
Benzinga
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022
November 05, 2022
From
89bio, Inc.
Via
GlobeNewswire
ServiceNow, Teladoc Health And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
October 27, 2022
U.S. stock futures traded mostly higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
$9 Million Bet On 89bio? 3 Stocks Insiders Are Buying
October 21, 2022
Although US stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
AVEO Pharmaceuticals, Akouos And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
October 18, 2022
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Where 89bio Stands With Analysts
August 17, 2022
Analysts have provided the following ratings for 89bio (NASDAQ:ETNB) within the last quarter:
Via
Benzinga
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
October 13, 2022
From
89bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
September 16, 2022
Via
Benzinga
Analyst Ratings for 89bio
September 14, 2022
Over the past 3 months, 7 analysts have published their opinion on 89bio (NASDAQ:ETNB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 13, 2022
Via
Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
September 14, 2022
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...
Via
Benzinga
US Stocks Open Lower After Inflation Report, Dow Dips 700 Points
September 13, 2022
U.S. stocks traded sharply lower this morning, following the release of inflation data for August
Via
Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
September 13, 2022
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 13, 2022
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares!
Via
InvestorPlace
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 26, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
August 26, 2022
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 18, 2022
Via
Benzinga
89bio Shares Climb After Concluding Enrolment In Mid-Stage NASH Study
August 18, 2022
89bio (NASDAQ: ETNB) has completed enrollment in ENLIVEN, the Phase 2b trial of pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH).
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 17, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.